EGFR positive

TQB2440 showed equivalent efficacy, comparable safety, PK, and immunogenicity profiles to reference pertuzumab in the neoadjuvant treatment of patients with HER2-positive early or locally advanced breast cancer.

Inpatient glucose monitoring enabled prompt detection of rapid glucose elevation and early intervention before the onset of DKA, resulting in a favorable outcome. Further clinical evidence is required to define optimal intervention strategies for grade 4 hyperglycemia associated with capivasertib therapy.

Higher CTC signature ITH was associated with increased Oncotype DX risk and higher overall grade. These findings highlight the value of our CTC signature in disease progression and the role of ITH on recurrence risk.

Postoperative intracranial recurrence after surgical resection of brain metastasis demonstrates distinct incidence rates, temporal profiles, and independent risk factors. These recurrence patterns and associated risks are highly dependent on the tumor type.

The patient recovered uneventfully, was discharged on the second day after surgery, received one year of trastuzumab monotherapy as the postoperative adjuvant therapy due to the patient's strong preference, and has been well for 14 months. Diagnostic physicians should note that unilateral fibrous disease of the breast should be evaluated with MRI before tissue sampling, and the change of posterior echoes is an important diagnostic clue for the diagnosis of breast cancer in the fibrous disease of the breast.

Omission of SLNB in patients with small HR-positive/HER2-negative tumors results in a missed indication for CDK4/6i in <8 % with minimal impact on recurrence.

Metformin and its derivatives exert dual anticancer effects by modulating systemic insulin signaling and targeting tumor-intrinsic pathways. Nevertheless, inconsistencies between preclinical efficacy and clinical outcomes highlight the need for biomarker-guided approaches and deeper investigation into tumour-specific metabolic contects. These complementary mechanisms highlight their potential in precision BC therapy, warranting biomarker-driven studies and optimized therapeutic combinations.

Patients who underwent upfront surgery had a greater likelihood of being pN+; however, there was no difference in the likelihood of axillary lymph node dissection. Therefore, neoadjuvant systemic therapy use should be based on current systemic therapy guidelines and patient-centered shared multidisciplinary decision-making.

Similarly, while clinical factors and imaging tools may help identify early on patients at higher risk of experiencing TIC, no cardioprotective strategy has yet demonstrated robust and conclusive benefit. Despite the emergence of newer anti-HER2 agents and evolving treatment paradigms, trastuzumab will probably continue to serve as a key therapeutic backbone, especially for patients with lower risk HER2+ eBC.

She was initiated on palbociclib and letrozole treatment in April 2024...She was commenced on ribociclib and letrozole for relapsed metastatic liver disease in April 2023...Understanding the role of CDK4/6 inhibition and the link with psoriasis is important for optimizing therapeutic choices for patients with cancer with pre-existing or newly developed psoriasis. Given the increasing use of CDK4/6 inhibitors in cancer treatment, clinicians should be vigilant of the potential increased prevalence of psoriasis experienced in this patient cohort.

Patients were randomized 1:1 to receive zolbetuximab plus chemotherapy or placebo plus chemotherapy (mFOLFOX6 [modified folinic acid, 5-fluorouracil, and oxaliplatin] or CAPOX [capecitabine and oxaliplatin]). Zolbetuximab plus chemotherapy demonstrated favorable PFS and OS versus placebo plus chemotherapy in the Korean subgroup, with numerically greater efficacy compared with the overall pooled population. This may be potentially attributable to low rates of zolbetuximab discontinuation and toxicity management.

This study suggests that selected patients with de novo mBC and locoregional oligoprogression can benefit from breast surgery while maintaining the same systemic treatment, particularly in the setting of HER2-positive disease or a pre-oligoprogression PFS >1 year.